Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Phase 1
25
about 1.4 years
18–65
1 site in MD
What this study is about
This trial is testing a treatment called fostamatinib in people with stable sickle cell disease. The goal is to see if this drug is safe and well-tolerated at different doses. Participants will take the drug twice daily for up to 6 weeks, and their health will be monitored through regular clinic visits.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Fostamatinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fostamatinib
oral (Oral Tablet)
Primary: The number of type, incidence, severity and relationship to study treatment of adverse events and serious adverse events
Secondary: Number of participants that discontinued fostamatinib due to adverse events following CTCAE.